Trends in multidrug-resistant tuberculosis

dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-20T13:34:31Z
dc.date.available2014-05-20T13:34:31Z
dc.date.created2014-05-20T13:34:31Z
dc.date.issued2008-01-01
dc.identifierJournal of Venomous Animals and Toxins Including Tropical Diseases. Botucatu: Cevap-unesp, v. 14, n. 2, p. 203-223, 2008.
dc.identifier1678-9199
dc.identifierhttp://hdl.handle.net/11449/11847
dc.identifierS1678-91992008000200003
dc.identifierWOS:000256791100003
dc.identifierS1678-91992008000200003-en.pdf
dc.description.abstractMultidrug-resistant tuberculosis (MDR-TB) is an increasing global problem. The extent and burden of MDR-TB varies significantly from country to country and region to region. Globally, about three per cent of all newly diagnosed patients have MDR-TB and the proportion is higher in patients who had previously received anti-tuberculosis (anti-TB) treatment reflecting the failure of programs designed to ensure complete cure of patients with tuberculosis. The management of MDR-TB is a challenge that should be undertaken by experienced clinicians at centers equipped with reliable laboratory services and implementation of DOTS-Plus strategy.
dc.languageeng
dc.publisherUniversidade Estadual Paulista (Unesp), Centro de Estudos de Venenos e Animais Peçonhentos (CEVAP)
dc.relationJournal of Venomous Animals and Toxins Including Tropical Diseases
dc.relation1.782
dc.relation0,573
dc.rightsAcesso aberto
dc.sourceWeb of Science
dc.subjecttuberculosis
dc.subjectMDR-TB
dc.subjectXDR-TB
dc.subjectDOTS
dc.subjectDOTS-Plus
dc.titleTrends in multidrug-resistant tuberculosis
dc.typeOtros


Este ítem pertenece a la siguiente institución